Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The study led by MRC WIMM researchers as part of an international team aims to understand what happens when patients stop responding to treatment.

3D image of red blood cells

Acute Myeloid Leukaemia (AML) is the most common and aggressive blood cancer in adults and is incurable in most patients. About 12-15% of AML patients have a mutation in the IDH2 gene that stops bone marrow cells from differentiating, or maturing, into blood cells that are required for life. Instead, these immature cells accumulate in the bone marrow and blood, which is a hallmark of AML. 

Find out more (MRC Weatherall Institute of Molecular Medicine website)